2.53
-0.13(-4.89%)
Currency In USD
| Previous Close | 2.66 |
| Open | 2.65 |
| Day High | 2.69 |
| Day Low | 2.42 |
| 52-Week High | 8.4 |
| 52-Week Low | 2.3 |
| Volume | 887,754 |
| Average Volume | 1.36M |
| Market Cap | 277.57M |
| PE | -2.5 |
| EPS | -1.01 |
| Moving Average 50 Days | 3.62 |
| Moving Average 200 Days | 5.35 |
| Change | -0.13 |
If you invested $1000 in Annexon, Inc. (ANNX) since IPO date, it would be worth $142.45 as of March 14, 2025 at a share price of $2.53. Whereas If you bought $1000 worth of Annexon, Inc. (ANNX) shares 3 years ago, it would be worth $685.64 as of March 14, 2025 at a share price of $2.53.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Annexon Biosciences to Present at the TD Cowen 45th Annual Health Care Conference
GlobeNewswire Inc.
Feb 26, 2025 9:05 PM GMT
BRISBANE, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflamma
Annexon Announces Presentations Highlighting ANX007 Functional and Structural Differentiation in Geographic Atrophy at the Macula Society 48th Annual Meeting
GlobeNewswire Inc.
Feb 13, 2025 1:30 PM GMT
Data Reinforce Neuroprotective Effect of C1q Blockade with ANX007 Against Inflammation and Neuronal DamageBRISBANE, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical
Annexon Provides 2025 Outlook with Strong Momentum Accelerating into Breakthrough Year
GlobeNewswire Inc.
Jan 13, 2025 1:00 PM GMT
ANX005 First Potential Targeted Therapy for Guillain-Barré Syndrome Advancing Towards 1H 2025 BLA Submission ANX007 First Potential Neuroprotective Therapy for Geographic Atrophy Expected to Complete Enrollment of Phase 3 ARCHER II Trial in 2H 2025 A